XENOTHERA to raise Series A

XENOTHERA has started to gather investors for a Series A round of funding that will occur in 2019.

This upcoming round will finance an highly anticipated first-in-human trial that will start this year. After amazing pre-clinical and toxicology data in 2018, XENOTHERA’S LIS1 is ready for clinical tests. As per the nature of the product there will be no phase I and we are excited to jump onto the phase II.

Stay tuned for the upcoming publications regarding pre-clinical analysis.